Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis
暂无分享,去创建一个
Winnie S. Liang | J. Trent | M. Neff | W. Tembe | N. Hayward | M. Huentelman | V. Zismann | W. Liang | M. Stark | D. Thamm | W. Hendricks | C. Khanna | M. Breen | A. Ruhe | C. Legendre | J. Kiefer | K. Sivaprakasam | N. Perdigones | J. Aldrich | B. Davis | N. Duesbery | K. Poorman | V. Deluca | R. Froman | M. Washington | G. Post | K. Brown | Alexander Sekulic | Waibhav Tembe | Karthigayini Sivaprakasam | William P. D. Hendricks | Christophe Legendre | Kevin Brown
[1] Henning Hermjakob,et al. The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..
[2] Catherine A. Shang,et al. Whole-genome landscapes of major melanoma subtypes , 2017, Nature.
[3] Rebecca F. Halperin,et al. Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. , 2017, Genome research.
[4] K. Brown,et al. The genomic landscape of cutaneous melanoma , 2016, Pigment cell & melanoma research.
[5] Mark Dewhirst,et al. Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology , 2016, Science Translational Medicine.
[6] Henning Hermjakob,et al. The Reactome pathway Knowledgebase , 2015, Nucleic acids research.
[7] M. Kennard,et al. Measuring benefits of protected area management: trends across realms and research gaps for freshwater systems , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.
[8] E. Mauceli,et al. Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background , 2015, Genome research.
[9] D. Gustafson,et al. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. , 2015, Veterinary and comparative oncology.
[10] Matthew Breen,et al. Comparative oncology: what dogs and other species can teach us about humans with cancer , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.
[11] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[12] M. Breen,et al. BRAF Mutations in Canine Cancers , 2015, PloS one.
[13] Kathleen M Spring,et al. The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis , 2015, Oncogene.
[14] Ryan D. Morin,et al. Genetic inactivation of TRAF3 in canine and human B-cell lymphoma. , 2015, Blood.
[15] J. Wolchok,et al. Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[17] A. Motsinger-Reif,et al. Comparative cytogenetic characterization of primary canine melanocytic lesions using array CGH and fluorescence in situ hybridization , 2014, Chromosome Research.
[18] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[19] Jimmy Lin,et al. Mutational and Functional Analysis of the Tumor‐Suppressor PTPRD in Human Melanoma , 2014, Human mutation.
[20] Shaying Zhao,et al. Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer. , 2014, Cancer research.
[21] G. Stamp,et al. The mutational burden of acral melanoma revealed by whole‐genome sequencing and comparative analysis , 2014, Pigment cell & melanoma research.
[22] Kathleen M Spring,et al. Phosphorylation of DEP-1/PTPRJ on threonine 1318 regulates Src activation and endothelial cell permeability induced by vascular endothelial growth factor. , 2014, Cellular signalling.
[23] P. Meltzer,et al. Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma , 2014, Clinical Cancer Research.
[24] R. Bernards,et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.
[25] Daniel M. Rotroff,et al. Genomic profiling reveals extensive heterogeneity in somatic DNA copy number aberrations of canine hemangiosarcoma , 2014, Chromosome Research.
[26] F. Galibert,et al. Naturally occurring melanomas in dogs as models for non‐UV pathways of human melanomas , 2014, Pigment cell & melanoma research.
[27] Jaime Rodriguez-Canales,et al. Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma , 2013, Pigment cell & melanoma research.
[28] J. Carpten,et al. Long insert whole genome sequencing for copy number variant and translocation detection , 2013, Nucleic acids research.
[29] Shaying Zhao,et al. Cancer driver-passenger distinction via sporadic human and dog cancer comparison: a proof of principle study with colorectal cancer , 2013, Oncogene.
[30] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[31] Mauricio O. Carneiro,et al. From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.
[32] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[33] G. Stamp,et al. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma , 2013, The Journal of pathology.
[34] A. Liao,et al. KIT gene exon 11 mutations in canine malignant melanoma. , 2013, Veterinary journal.
[35] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[36] Sean Davis,et al. Chromothripsis and focal copy number alterations determine poor outcome in malignant melanoma. , 2013, Cancer research.
[37] Lynda Chin,et al. Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.
[38] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[39] Giovanni Parmigiani,et al. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation , 2013, Proceedings of the National Academy of Sciences.
[40] K. Lindblad-Toh,et al. The genomic signature of dog domestication reveals adaptation to a starch-rich diet , 2013, Nature.
[41] J. Dobson. Breed-Predispositions to Cancer in Pedigree Dogs , 2013, ISRN veterinary science.
[42] W. Sellers,et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.
[43] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[44] J. Carpten,et al. Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs , 2013 .
[45] V. Thayanithy,et al. A genome-wide approach to comparative oncology: high-resolution oligonucleotide aCGH of canine and human osteosarcoma pinpoints shared microaberrations. , 2012, Cancer genetics.
[46] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[47] J. Miller,et al. Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.
[48] Thomas Zichner,et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis , 2012, Bioinform..
[49] A. Sivachenko,et al. A Landscape of Driver Mutations in Melanoma , 2012, Cell.
[50] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[51] Matthew J. Davis,et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.
[52] M. Meyerson,et al. Recurrent Hemizygous Deletions in Cancers May Optimize Proliferative Potential , 2012, Science.
[53] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[54] A. Børresen-Dale,et al. Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.
[55] S. Scholl,et al. Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ. , 2012, Blood.
[56] Wendy S. W. Wong,et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..
[57] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[58] Pablo Cingolani,et al. © 2012 Landes Bioscience. Do not distribute. , 2022 .
[59] T. Fennell,et al. Melanoma genome sequencing reveals frequent PREX2 mutations , 2012, Nature.
[60] A. Ashworth,et al. Whole genome sequencing of matched primary and metastatic acral melanomas. , 2012, Genome research.
[61] David T. W. Jones,et al. Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations , 2012, Cell.
[62] R. Wilson,et al. Chromothripsis and Human Disease: Piecing Together the Shattering Process , 2012, Cell.
[63] R. Gibbs,et al. Frequent somatic MAP3K5 and MAP3K9 mutations in metastatic melanoma identified by exome sequencing , 2011, Nature Genetics.
[64] Susumu Goto,et al. KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..
[65] M. Ellersieck,et al. Identification of the most common cutaneous neoplasms in dogs and evaluation of breed and age distributions for selected neoplasms. , 2011, Journal of the American Veterinary Medical Association.
[66] K. Lindblad-Toh,et al. Identification of Genomic Regions Associated with Phenotypic Variation between Dog Breeds using Selection Mapping , 2011, PLoS genetics.
[67] H. Sakai,et al. Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas. , 2011, Veterinary and comparative oncology.
[68] C. Mawrin,et al. Loss of the Protein‐Tyrosine Phosphatase DEP‐1/PTPRJ Drives Meningioma Cell Motility , 2011, Brain pathology.
[69] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[70] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[71] Kristina Masson,et al. Protein-tyrosine Phosphatase DEP-1 Controls Receptor Tyrosine Kinase FLT3 Signaling* , 2011, The Journal of Biological Chemistry.
[72] N. Carter,et al. Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.
[73] M. Kiupel,et al. Immunohistochemical Diagnosis of Canine Oral Amelanotic Melanocytic Neoplasms , 2011, Veterinary pathology.
[74] C. Croce,et al. Role of PTPRJ genotype in papillary thyroid carcinoma risk. , 2010, Endocrine-related cancer.
[75] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[76] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[77] Joshua F. McMichael,et al. Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.
[78] Tom Royce,et al. A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.
[79] 三田 雄一郎. Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers , 2010 .
[80] S. Toyooka,et al. Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers , 2010, Journal of Cancer Research and Clinical Oncology.
[81] P. Mischel,et al. An Unbiased Screen Identifies DEP-1 Tumor Suppressor as a Phosphatase Controlling EGFR Endocytosis , 2009, Current Biology.
[82] Chris Sander,et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers , 2009, Proceedings of the National Academy of Sciences.
[83] L. Castagnoli,et al. Tumor Suppressor Density-enhanced Phosphatase-1 (DEP-1) Inhibits the RAS Pathway by Direct Dephosphorylation of ERK1/2 Kinases* , 2009, The Journal of Biological Chemistry.
[84] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[85] Pornpimol Charoentong,et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks , 2009, Bioinform..
[86] T. Ryken,et al. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. , 2008, Cancer research.
[87] R. de Bree,et al. Head and neck mucosal melanoma: Experience with 42 patients, with emphasis on the role of postoperative radiotherapy , 2008, Head & neck.
[88] Kathleen M Spring,et al. New Role for the Protein Tyrosine Phosphatase DEP-1 in Akt Activation and Endothelial Cell Survival , 2008, Molecular and Cellular Biology.
[89] S. Gruber,et al. PTPRJ Haplotypes and Colorectal Cancer Risk , 2008, Cancer Epidemiology Biomarkers & Prevention.
[90] M. Ceppi,et al. Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. , 2008, Journal of veterinary internal medicine.
[91] R. Stallings,et al. Aberrant splicing of the PTPRD gene mimics microdeletions identified at this locus in neuroblastomas , 2008, Genes, chromosomes & cancer.
[92] M. Paoloni,et al. Translation of new cancer treatments from pet dogs to humans , 2008, Nature Reviews Cancer.
[93] J. Wolchok,et al. Of Mice and Men (and Dogs): development of a xenogeneic DNA vaccine for canine oral malignant melanoma , 2008 .
[94] P. Bergman. Canine oral melanoma. , 2007, Clinical techniques in small animal practice.
[95] N. Hayward,et al. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. , 2007, Cancer research.
[96] A. Östman,et al. DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients , 2006, Oncogene.
[97] D. Pinkel,et al. Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] C. Croce,et al. Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis. , 2006, DNA and cell biology.
[99] James A. Cuff,et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog , 2005, Nature.
[100] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[101] Nicholas J Wareham,et al. Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. , 2005, Human molecular genetics.
[102] S. Knuutila,et al. CDK4 is a probable target gene in a novel amplicon at 12q13.3–q14.1 in lung cancer , 2005, Genes, chromosomes & cancer.
[103] J. McCallan,et al. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas , 2005, Mammalian Genome.
[104] H. Oka,et al. A study on the image diagnosis of melanoma , 2004, The 26th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
[105] A. Fusco,et al. The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis , 2004, Oncogene.
[106] C. Croce,et al. Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. , 2004, Carcinogenesis.
[107] M. Wigler,et al. Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.
[108] J. Shah,et al. Primary mucosal melanoma of the head and neck , 2004, Cancer.
[109] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[110] Ajay N. Jain,et al. Determinants of BRAF mutations in primary melanomas. , 2003, Journal of the National Cancer Institute.
[111] G. Meijer,et al. LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12–21 , 2003, Oncogene.
[112] M. Corada,et al. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, β-catenin, and the phosphatase DEP-1/CD148 , 2003, The Journal of cell biology.
[113] N. Tonks,et al. Hepatocyte Growth Factor Receptor Tyrosine Kinase Met Is a Substrate of the Receptor Protein-tyrosine Phosphatase DEP-1* , 2003, The Journal of Biological Chemistry.
[114] P. Meltzer,et al. High frequency of BRAF mutations in nevi , 2003, Nature Genetics.
[115] M. Goldschmidt,et al. A Comparative Review of Melanocytic Neoplasms , 2002, Veterinary pathology.
[116] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[117] Cestmir Vlcek,et al. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers , 2002, Nature Genetics.
[118] J. Wood,et al. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. , 2002, The Journal of small animal practice.
[119] G. Viglietto,et al. Rat Protein Tyrosine Phosphatase η Suppresses the Neoplastic Phenotype of Retrovirally Transformed Thyroid Cells through the Stabilization of p27Kip1 , 2000, Molecular and Cellular Biology.
[120] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[121] M. Turker. Somatic cell mutations: can they provide a link between aging and cancer? , 2000, Mechanisms of Ageing and Development.
[122] R. Vilella,et al. Site-selective Dephosphorylation of the Platelet-derived Growth Factor β-Receptor by the Receptor-like Protein-tyrosine Phosphatase DEP-1* , 2000, The Journal of Biological Chemistry.
[123] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[124] L. Karnell,et al. The National Cancer Data Base report on cutaneous and noncutaneous melanoma , 1998, Cancer.
[125] M. Goldschmidt. Histological classification of epithelial and melanocytic tumors of the skin of domestic animals , 1998 .
[126] Spiros Manolidis,et al. Malignant mucosal melanoma of the head and neck , 1997, Cancer.
[127] G. Viglietto,et al. Thyroid cell transformation inhibits the expression of a novel rat protein tyrosine phosphatase. , 1997, Experimental cell research.
[128] P. Meltzer,et al. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. , 1996, Cancer research.
[129] S. Lipkowitz,et al. The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. , 1996, Cancer research.
[130] C. Disteche,et al. Cloning and characterization of rat density-enhanced phosphatase-1, a protein tyrosine phosphatase expressed by vascular cells. , 1996, Circulation research.
[131] N. Tonks,et al. Expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is enhanced with increasing cell density. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[132] R. Albert,et al. Life span and cancer mortality in the beagle dog and humans , 1994, Mechanisms of Ageing and Development.
[133] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[134] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[135] J. Reif,et al. Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital. , 1974, Cancer research.
[136] M. Klauber,et al. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. , 1968, Journal of the National Cancer Institute.
[137] E. Cotchin. Melanotic tumours of dogs. , 1955, Journal of comparative pathology.